{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:11:02Z","timestamp":1781194262185,"version":"3.54.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>In the absence of clinical efficacy data, vaccine protective effect can be extrapolated from animals to humans, using an immunological biomarker in humans that correlates with protection in animals, in a statistical approach called immunobridging. Such an immunobridging approach was previously used to infer the likely protective effect of the heterologous two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen. However, this immunobridging model does not provide information on how the persistence of the vaccine-induced immune response relates to durability of protection in humans.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>In both humans and non-human primates, vaccine-induced circulating antibody levels appear to be very stable after an initial phase of contraction and are maintained for at least 3.8 years in humans (and at least 1.3 years in non-human primates). Immunological memory was also maintained over this period, as shown by the kinetics and magnitude of the anamnestic response following re-exposure to the Ebola virus glycoprotein antigen via booster vaccination with Ad26.ZEBOV in humans. In non-human primates, immunological memory was also formed as shown by an anamnestic response after high-dose, intramuscular injection with Ebola virus, but was not sufficient for protection against Ebola virus disease at later timepoints due to a decline in circulating antibodies and the fast kinetics of disease in the non-human primates model. Booster vaccination within three days of subsequent Ebola virus challenge in non-human primates resulted in protection from Ebola virus disease, i.e. before the anamnestic response was fully developed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Humans infected with Ebola virus may benefit from the anamnestic response to prevent disease progression, as the incubation time is longer and progression of Ebola virus disease is slower as compared to non-human primates. Therefore, the persistence of vaccine-induced immune memory could be considered as a potential correlate of long-term protection against Ebola virus disease in humans, without the need for a booster.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1215302","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T08:28:36Z","timestamp":1693556916000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans"],"prefix":"10.3389","volume":"14","author":[{"given":"Chelsea","family":"McLean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Dijkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auguste","family":"Gaddah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babajide","family":"Keshinro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Katwere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macaya","family":"Douoguih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Solforosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Czapska-Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Dekking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Wollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Volkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Pau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Callendret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Sadoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Luhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Roozendaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"B1","unstructured":"History of ebola virus disease (EVD) outbreaks2023"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26-and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA - J Am Med Assoc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.20644","article-title":"Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored ebola vaccines at 1 year","volume":"317","author":"Winslow","year":"2017","journal-title":"JAMA - J Am Med Assoc"},{"key":"B4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/infdis\/jiz070","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-filo ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania","volume":"220","author":"Anywaine","year":"2019","journal-title":"J Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/infdis\/jiz071","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccine regimen with ad26.ZEBOV and MVA-BN-filo ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya","volume":"220","author":"Mutua","year":"2019","journal-title":"J Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1003813","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa","volume":"18","author":"Barry","year":"2021","journal-title":"PloS Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-021-00402-8","article-title":"Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen","volume":"6","author":"Bockstal","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00128-6","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial","volume":"22","author":"Afolabi","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1003865","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial","volume":"19","author":"Anywaine","year":"2022","journal-title":"PloS Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200072","article-title":"Randomized trial of vaccines for zaire ebola virus disease","volume":"387","author":"Kieh","year":"2022","journal-title":"New Engl J Med United States"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0274906","article-title":"First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study","volume":"17","author":"Bockstal","year":"2022","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/infdis\/jiaa586","article-title":"Safety and immunogenicity of heterologous and homologous 2-dose regimens of adenovirus serotype 26\u2013 and modified vaccinia ankara\u2013vectored ebola vaccines: A randomized, controlled phase 1 study","volume":"226","author":"Goldstein","year":"2022","journal-title":"J Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","volume":"22","author":"Ishola","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(22)00594-1","article-title":"Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial","volume":"23","author":"Manno","year":"2022","journal-title":"Lancet Infect Dis Elsevier Ltd"},{"key":"B16","unstructured":"Ebola virus disease fact sheet2023"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-020-00261-9","article-title":"Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate","volume":"5","author":"Roozendaal","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-022-00564-z","article-title":"Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola","volume":"7","author":"Bockstal","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/v4123511","article-title":"Standardization of the filovirus plaque assay for use in preclinical studies","volume":"4","author":"Shurtleff","year":"2012","journal-title":"Viruses"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0215457","article-title":"Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples","volume":"14","author":"Rudge","year":"2019","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/jvi.00579-19","article-title":"Dynamics of the humoral immune response to a prime-boost ebola vaccine: quantification and sources of variation","volume":"93","author":"Pasin","year":"2019","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat Med United States"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.00597-19.00597-19","article-title":"crossm antiviral innate responses induced by VSV-EBOV vaccination","volume":"10","author":"Menicucci","year":"2019","journal-title":"MBio"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy316","article-title":"Role of antibodies in protection against ebola virus in nonhuman primates immunized with three vaccine platforms","volume":"218","author":"Warfield","year":"2018","journal-title":"J Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.07.044.Antibody","article-title":"Antibody repertoires to the same ebola vaccine antigen are differentially affected by vaccine vectors","volume":"24","author":"Meyer","year":"2018","journal-title":"Cell Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112402","article-title":"Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates","volume":"42","author":"Gunn","year":"2023","journal-title":"Cell Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz657","article-title":"Antibody-dependent natural killer cell activation after ebola vaccination","volume":"223","author":"Wagstaffe","year":"2021","journal-title":"J Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-06226-8","article-title":"Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind Fc\u03b3RI","volume":"7","author":"Radinsky","year":"2017","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v12090915","article-title":"Ebola virus disease survivors show more efficient antibody immunity than vaccinees despite similar levels of circulating immunoglobulins","volume":"12","author":"Koch","year":"2020","journal-title":"Viruses"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq6364","article-title":"A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates","volume":"14","author":"Hunegnaw","year":"2022","journal-title":"Sci Trans Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4161\/hv.4.4.5751","article-title":"Protective immunity following vaccination: How is it defined","volume":"4","author":"Amanna","year":"2008","journal-title":"Hum Vaccines"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.10.101","article-title":"Conference report Hepatitis B vaccination : A completed schedule enough to control HBV lifelong","volume":"31","author":"FitzSimons","year":"2013","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(20)30198-1","article-title":"\u2018Estimation of the correlates of protection of the rVSV\u0394G-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2\/3 clinical trials\u2019, The Lancet Microbe. The Author(s)","volume":"2","author":"Grais","year":"2021","journal-title":"Published by Elsevier Ltd. This is an Open Access Article under CC BY 4.0 license"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1109486","article-title":"Approaches to demonstrating the effectiveness of filovirus vaccines: Lessons from Ebola and COVID-19","volume":"14","author":"Gruber","year":"2023","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2014.0066","article-title":"Immune evasion in ebolavirus infections","volume":"28","author":"Audet","year":"2015","journal-title":"Viral Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1215302\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T08:28:40Z","timestamp":1693556920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1215302\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2023.1215302"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1215302","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"article-number":"1215302"}}